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PROTOCOL
Metabolic side effects of antipsychotic 
drugs in individuals with schizophrenia 
during medium‑ to long‑term treatment: 
protocol for a systematic review and network 
meta‑analysis of randomized controlled trials
Johannes Schneider‑Thoma1*† , Angelika Kapfhammer1†, Dongfang Wang1, Irene Bighelli1, Spyridon Siafis1, 
Hui Wu1,2, Wulf‑Peter Hansen3, John M. Davis4,5, Georgia Salanti6 and Stefan Leucht1 
Abstract 
Background: Antipsychotic drugs and especially the newer compounds are known to cause metabolic side effects. 
However, a comprehensive comparison of the different substances regarding their propensity to cause metabolic side 
effects in medium‑ to long‑term treatment of schizophrenia is lacking.
Methods: We will conduct a systematic review and network meta‑analysis (NMA). We will include randomized 
controlled trials (RCTs) in which participants received either placebo or an antipsychotic (i.e. placebo‑controlled 
trials and head‑to‑head comparisons of drugs). We will include studies in individuals with schizophrenia or related 
disorders (such as schizophreniform or schizoaffective disorders) at any stage of the disease (acute episode; main‑
tenance phase). We will include studies with a duration of more than 3 months (medium‑ to long‑term treatment). 
The primary outcome will be the change in body weight. Secondary outcomes will be the further metabolic param‑
eters: fastening glucose, total cholesterol, low‑density lipoprotein (LDL) cholesterol, high‑density lipoprotein (HDL) 
cholesterol and triglycerides. We will search for eligible studies (independent of the publication status) in Cochrane 
Schizophrenia Group’s Study‑Based Register of Trials, which is compiled by regular searches in trial registries and 
multiple electronic databases from their inception onwards including MEDLINE, EMBASE and PsycINFO. Additionally, 
we will search previously published systematic reviews and websites of pharmaceutical companies for eligible stud‑
ies. At least two reviewers will independently conduct the process of study selection and data extraction. We will use 
the Cochrane Risk of Bias 2 tool to evaluate the risk of bias in studies. We will conduct random‑effects NMA within a 
Bayesian framework to synthesize all evidence for each outcome. We will conduct sensitivity and subgroup analyses 
to assess the robustness of the findings and to explore heterogeneity. The confidence in the results will be evaluated 
using the Confidence in Network Meta‑Analysis (CINeMA) framework.
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Background
Schizophrenia is a debilitating and often life-long dis-
order that ranks among the 20 top causes of disability 
according to the Global Burden of Disease Study [1]. 
Antipsychotic drugs are the mainstay of the treatment 
of schizophrenia. They are proven to be effective for the 
acute phase [2] and for recurrence prophylaxis [3], and 
many individuals take antipsychotics for years, or even 
lifetime [4, 5]. However, antipsychotics cause important 
side effects, most importantly extrapyramidal motor dis-
orders, increase in prolactin and metabolic side effects 
[6]. Metabolic side effects comprise weight gain, distur-
bances in cholesterol and triglyceride metabolism (dys-
lipidaemia) and dysregulation of glucose homeostasis 
(insulin resistance extending in diabetes) [7]. Obesity, 
dyslipidaemia and insulin resistance are key components 
of the metabolic syndrome [8–13] and are associated with 
important somatic diseases such as cardiovascular disor-
ders, stroke and diabetes [14]. Thereby, metabolic side 
effects of antipsychotics are likely to contribute to the on 
average 14.5  years reduced life-span of individuals with 
schizophrenia [15]. Moreover, weight gain is an impor-
tant subjective factor reducing the quality of life among 
persons with schizophrenia [16]. As a consequence, met-
abolic side effects are also linked to drug non-adherence 
[17], resulting in poor treatment outcomes and psychotic 
relapses. The decision of clinicians and individuals with 
schizophrenia which antipsychotic compound to use is 
often based on the profile of side effects because antip-
sychotic substances do not differ much in efficacy, but 
enormously in side effects [6]. Therefore, it is a field of big 
interest and ongoing research.
Recently Pillinger et  al. [18] conducted a network 
meta-analysis focussing on the comparative effects of 18 
antipsychotics on metabolic function during short-term 
treatment of patients with schizophrenia. The median 
treatment duration of the included trials was 6  weeks 
(IQR 6–8). However, it can be assumed that the meta-
bolic side effects have not peaked after few weeks of 
treatment yet, and data of longer treatment duration 
could differ. Up to date, it is unknown how antipsychotic 
compounds differ in extent and time pattern of caus-
ing metabolic side effects in medium- to long-term use. 
Pérez-Iglesias et al. [19] observed changes in weight and 
lipids especially during the course of the first year (in a 
cohort of first episode patients treated with haloperidol, 
olanzapine and risperidone for up to 3  years). Millen 
et al. [20] showed in a pooled analysis of 86 clinical tri-
als including adults treated with the oral or depot formu-
lations of olanzapine that weight increases most rapidly 
in the first 3 months of treatment, and then the increase 
slows down but continues, tending to reach a plateau 
after 6–12  months. De Hert et  al. [7] assumed that the 
greatest amount of weight gain associated with antipsy-
chotic therapy in previously drug-naive individuals with 
schizophrenia occurs on a scale of few months. Thus, 
analysing the metabolic parameters after several months 
of treatment in an expected nearly “steady-state” can 
deliver important information on how antipsychotics dif-
fer in the medium- to long-term treatment. To date, evi-
dence is still fragmentary, and there is no comprehensive 
comparison of this kind.
Objective
The objective is to estimate relative propensities of antip-
sychotic drugs to cause metabolic side effects in medium- 
to long-term treatment of individuals with schizophrenia, 
in terms of the following:
1. Weight gain.
2. Disturbances in lipid and glucose metabolism.
Methods
This systematic review and network meta-analysis is reg-
istered in the PROSPERO database (registration num-
ber: CRD42020175414). This protocol is being reported 
in accordance with the reporting guidance provided in 
the Preferred Reporting Items for Systematic Review and 
Meta-Analysis Protocols (PRISMA-P) statement [21] (see 
checklist in Additional file 1). In reporting the methods 
and results in the final report, we will follow the PRISMA 
2020 statement [22] and the extension for reporting net-
work meta-analysis of healthcare interventions [23].
Discussion: This systematic review and network meta‑analysis will provide a synthesis of the existing evidence from 
RCTs how antipsychotic drugs differ in terms of metabolic side effects during medium‑ to long‑term treatment. The 
findings have the potential to influence the choice of antipsychotic medication made by individuals with schizophre‑
nia and their physicians.
Systematic review registration: PROSPERO CRD42 02017 5414
Keywords: Network meta‑analysis, Antipsychotic drugs, Metabolic, Schizophrenia, Randomized controlled trials, 
Weight, Cholesterol, Triglyceride, Glucose
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Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) in which partici-
pants received either a placebo or an antipsychotic (i.e. 
placebo-controlled trials and head-to-head compari-
sons of drugs) will be included. Studies whose rand-
omization process is at high risk of bias (according to 
Cochrane Risk of Bias 2 [24]) will be excluded.
We will accept open and blinded RCTs. We will 
include studies with a minimum duration of 3 months, 
which is medium- to long-term treatment according 
to the classification of the Cochrane Schizophrenia 
Group. In case of cross-over studies, we will use only 
the first cross-over phase in order to avoid the problem 
of carryover effects which are very likely in drugs for 
schizophrenia [25]. We will exclude cluster-randomized 
trials to avoid intransitivity compared to patient-rand-
omized trials. There will be no language restriction to 
minimize “language bias” [26]. We will exclude studies 
from Mainland China because of serious quality con-
cerns previously described in the literature [27–29]. 
To include the high number of Chinese studies without 
clarifying their study quality has the risk of introduc-
ing an important bias in the results. But like observed 
in a past project of ours [30], and also described by 
Tong et al. [28], it is difficult to contact Chinese authors 
and obtain information to clear out quality concerns. 
An exception is studies conducted in China by inter-
national drug companies that ensure high-quality 
standards.
Types of participants
Participants are individuals with a diagnosis of schizo-
phrenia or related disorders (such as schizophreniform 
or schizoaffective disorders). There is no clear evidence 
that the latter schizophrenia-like psychoses are caused 
by fundamentally different disease processes or require 
different treatment approaches [31]. We will include 
trials irrespective of the diagnostic criteria used follow-
ing the strategy of the Cochrane Schizophrenia Group 
[32]. This decision should increase generalizability and 
representativeness. Nevertheless, we will exclude stud-
ies that did not use operationalized criteria such as 
ICD-10 or DSM-IV in a sensitivity analysis.
There will be no restrictions in terms of gender, eth-
nicity, age or setting (inpatients or outpatients). Also, 
we will include individuals irrespective of the stage of 
the disease (acute episode; maintenance phase) because 
the occurrence of side effects can be considered largely 
independent of psychopathology at study start.
Interventions and comparators
We will include placebo and a broad collection of antip-
sychotic drugs, comprising all newer antipsychotics 
developed in the last decades (formerly called second-
generation antipsychotics (SGAs)) and the clinically 
most important older antipsychotics (formerly called 
first-generation antipsychotics (FGAs)) (agents are 
listed in the “Search strategy” section). The choice of 
the latter was informed by a survey of international 
schizophrenia experts [33].
We will include all these compounds in any form of 
administration, oral or as intramuscular depot. If an 
antipsychotic is available in both, oral and depot form, 
both formulations will be used as separate interventions 
in the network, because there are indications that oral 
and depot applications can differ in propensity to cause 
side effects [34], e.g. due to pharmacokinetic or compli-
ance issues [35]. Only short-acting intramuscular antip-
sychotics will be excluded because these are exclusively 
used in emergency situations nowadays. In fixed-dose 
studies, we will only include target to maximum doses 
according to the International Consensus Study on 
Antipsychotic Dosing [36]. All flexible-dose treatment 
regimens will be included, because these allow the inves-




Our primary outcome is weight gain measured in kilo-
grammes. Body weight is easy to measure and frequently 
used in clinical practice.
We will extract also other outcomes used to describe 
body weight, namely body mass index (BMI), waist cir-
cumference and number of study participants over-
weight, obese, with clinically significant weight gain 
(typically defined as weight gain ≥ 7% of baseline weight) 
and increased waist circumference. We plan to analyse 
these parameters as secondary outcomes only when suf-
ficient data is available.
Secondary outcomes
Because reporting of metabolic side effects is not stand-
ardized in trials of schizophrenia, we will extract different 
parameters for the other domains of the metabolic syn-
drome (laboratory measures taken from blood samples) 
and plan to analyse for each domain the parameter with 
the most data available:
1. Glucose metabolism: levels of fastening glucose, gly-
cated haemoglobin (HbA1c), homeostatic model 
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assessment of insulin resistance (HOMA-IR) and 
insulin and number of study participants with 
impaired fastening glucose and increased HbA1c.
2. Disturbances in total cholesterol metabolism: total 
cholesterol and number of study participants with 
hypercholesterinaemia.
3. Disturbances in low-density lipoprotein (LDL) cho-
lesterol metabolism: LDL cholesterol and number of 
study participants with increased LDL cholesterol.
4.  Disturbances in high-density lipoprotein (HDL) cho-
lesterol metabolism: HDL cholesterol and number of 
study participants with reduced HDL cholesterol.
5. Disturbances in triglyceride metabolism: triglycerides 
and number of study participants with hypertriglyc-
eridaemia.
The pathological thresholds of these parameters (rel-
evant for the dichotomous outcome measures) will be 
used as defined by the original study authors.
Time point of outcome measurement
We will analyse the outcomes at more than 3  months, 
which is medium/long-term according to the Cochrane 




The literature search will be conducted in Cochrane 
Schizophrenia Group’s Study-Based Register of Trials 
with no date/time, language, document type and publica-
tion status limitations. This specialized register for clini-
cal trials of interventions for schizophrenia is compiled of 
regular searches in multiple electronic databases includ-
ing MEDLINE, EMBASE, Allied and Complementary 
Medicine (AMED), Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), PsycINFO, PubMed, 
US National Institute of Health Ongoing Trials Register 
(ClinicalTrials.gov), World Health Organization Inter-
national Clinical Trials Registry Platform (www. who. int/ 
ictrp), ProQuest Dissertations and Theses A&I and its 
quarterly update, and Chinese databases (Chinese Bio-
medical Literature Database, China Knowledge Resource 
Integrated Database and Wanfang) and their annual 
updates until the end of 2016 [37–40].
Because of poor reporting of outcomes in medical 
research [41], we do not limit the search adding specific 
outcomes so that we will have all the outcomes. In the 
Intervention Field of STUDY, we will search for all ref-
erences with the following antipsychotic compounds: 
(*Amisulpride* OR *Aripiprazole* OR *Asenapine* OR 
*Benperidol* OR *Brexpiprazole* OR *Cariprazine* OR 
*Chlorpromazine* OR *Clopenthixol* OR *Clozapine* 
OR *Flupentixol* OR *Fluphenazine* OR *Fluspirilene* 
OR *Haloperidol* OR *Iloperidone* OR *Levome-
promazine* OR *Loxapine* OR *Lumateperone* OR 
*Lurasidone* OR *Molindone* OR *Olanzapine* OR *Pal-
iperidone* OR *Penfluridol* OR *Perazine* OR *Perphen-
azine* OR *Pimozide* OR *Quetiapine* OR *Risperidone* 
OR *Sertindole* OR *Sulpiride* OR *Thioridazine* OR 
*Tiotixene* OR *Trifluoperazine* OR *Ziprasidone* OR 
*Zotepine* OR *Zuclopenthixol*).
A draft search for Cochrane Schizophrenia Group’s 
register is provided in Additional file  2 and the specific 
search strategies for the multiple electronic databases 
used to compile the register in Additional file 3.
Reference lists and other sources
We will check previously published relevant systematic 
reviews if the included studies met our inclusion crite-
ria as well. For missing information, we will contact via 
email the corresponding authors and the responsible 
drug companies of each included study published in the 
last 20 years.
Identification and selection of studies
We will list all studies identified through electronic and 
manual searches with citation, titles and abstracts in a 
reference management programme Citavi (Swiss Aca-
demic Software, Zurich, Switzerland). By inspecting 
all titles and abstracts, two authors will independently 
assess the eligibility of the potential studies identified in 
the literature searches. Disagreement will be resolved 
by discussion, and where doubt still remains, we will 
acquire the full article for further inspection. Once the 
full articles are obtained, at least two reviewers will inde-
pendently decide whether the studies meet the inclusion 
criteria described above. If disagreement cannot be clari-
fied by discussion, we will resolve it with a third reviewer 
or by consulting the study authors.
Data extraction
At least two reviewers will independently extract data 
from each included trial on standardized and specifically 
customized digital forms in a Microsoft Access database. 
The software will automatically detect any inconsisten-
cies in data extraction. Disagreement will be resolved by 
a discussion with a third reviewer or by seeking further 
information from the study authors.
We will collect the following data from each included 
study:
– Study characteristics: e.g. study citation, year of pub-
lication, sample size, diagnosis investigated and diag-
nostic criteria used, funding/sponsor and registration 
number to trial registries.
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– Characteristics of study participants: e.g. age, gender, 
ethnicity, baseline metabolic parameters and lifetime 
exposure to antipsychotics (if not available, duration 
of illness will be used as a proxy).
– Intervention details: e.g. compound, application 
form, dosage and treatment duration.
– Outcome measures of the primary and second-
ary outcomes (see above), including information on 
imputation methods to handle missing data and the 
timing of recording the outcome (in weeks after ran-
domization).
Effect size measures
The effect size for continuous outcomes will be mean 
differences (MD) and its 95% credibility intervals (CrIs). 
For missing standard deviations (SDs), we will proceed 
as described in Sect. 6.5.2. of the Cochrane Handbook for 
Systematic Reviews of Interventions [42]. Change data will 
be preferred over endpoint data. For dichotomous out-
comes, we will use odds ratio (OR) and its 95% CrIs.
Handling of missing outcome data
Estimates based on imputation methods to handle miss-
ing data (used by the original authors) will be preferred 
over completers’ data. Imputed data based on mixed-
models of repeated measurement (MMRM) or multiple 
imputations (MI) will be preferred over the last observa-
tion carried forward (LOCF), if available. For the primary 
outcome, we collect both, estimates based on imputation 
methods and completers’ data, to conduct the sensitivity 
analysis mentioned below.
Risk of bias assessment
Two reviewers will independently assess the risk of bias 
for the included studies using the revised Cochrane Risk 
of Bias Tool (RoB) 2 [24]. The following domains will be 
checked:
1. Risk of bias arising from the randomization process.
2. Risk of bias due to deviations from the intended 
interventions (effect of assignment to intervention).
3. Risk of bias due to missing outcome data.
4. Risk of bias in the measurement of the outcome.
5. Risk of bias in the selection of the reported result.
6. Overall risk of bias, as calculated by the algorithm 
suggested within this tool.
When disagreement between the two independent 
reviewers arises, we will resolve it through discussion 
and, if needed, a third senior author will be involved. 
Where necessary, we will contact the authors of the origi-
nal studies for further information. Effects of studies with 




We will generate descriptive statistics of study character-
istics (by study and overall), describing important clinical 
or methodological variables, such as age, gender, ethnic-
ity, baseline metabolic parameters, lifetime exposure to 
antipsychotics (if not available, duration of illness will 
be used as a proxy), antipsychotic dose, blinding, use of 
enriched design, sponsorship and study duration.
Assessment of the transitivity assumption
Joint analysis of different treatment comparisons can 
only provide valid findings if the network is transitive. 
That means that trial participants who fulfil the inclu-
sion criteria are equally likely to be randomized to any of 
the studies of interest (i.e. jointly randomizable) and that 
the observed comparisons do not differ with respect to 
the distribution of effect modifiers. We will assess this 
assumption epidemiologically by comparing the distribu-
tion of potential effect modifiers across studies grouped 
by comparison [43], namely age, sex, baseline weight, 
antipsychotic dose and study duration.
Assessment of heterogeneity
We will investigate heterogeneity (variability in relative 
treatment effects within the same treatment comparison) 
by visual inspection of forest plots and by estimating the 
between-study variance τ2 and with the I2 statistic. In the 
joint synthesis using NMA, we will assume the hetero-
geneity variance common across the various treatment 
comparisons and use empirical distributions to charac-
terize the amount of heterogeneity as low, moderate or 
high using the first and third quantiles [44, 45]. We will 
explore potential reasons for heterogeneity by subgroup 
analysis (see below).
Network meta‑analysis
Network meta-analysis (NMA) combines direct and 
indirect evidence for all relative treatment effects and 
can therefore provide estimates with maximum power 
and increased precision [46]. If the conditions for NMA 
are met (high likelihood of transitivity), we will perform 
random effects network meta-analyses using a mixture 
of frequentist (netmeta package for plotting the network 
and evaluate the inconsistency, as described below) and 
Bayesian methods (to fit the model and obtain all rela-
tive effects, using self-programmed routines and the 
rjags package) in the R software. A common heterogene-
ity parameter will be used in the model. Additionally, to 
assess how much the common heterogeneity affects the 
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relative effect with respect to the extra uncertainty antici-
pated in a future study, we will estimate the prediction 
intervals.
A league table will present the summary MDs or ORs 
for all pairwise comparisons. If the estimation of the 
treatment effects is relatively precise, we will compute 
the probability for the ranking of each intervention using 
surface under the cumulative ranking curve (SUCRA) 
[47].
If the requirements of network meta-analysis are not 
met (low likelihood of transitivity and/or large unex-
plained inconsistency, see below) we will use pairwise 
meta-analysis for data synthesis. We will perform fre-
quentist random effects pairwise meta-analysis in R using 
the meta package.
Geometry of the network
We will present the geometry of the networks by network 
plots. For each outcome, interventions which have been 
compared in clinical trials and for which data on the out-
come (direct evidence) is available will be linked by lines. 
The thickness of lines will correspond to the number 
of trials evaluating the comparison. This size of circles 
around each intervention will correspond to the number 
of participants assigned to the intervention. Additionally, 
we will indicate the compared interventions of each study 
in a “characteristics of included studies”-table (see above) 
and the “risk of bias”-tables to display the characteristics 
of interventions and comparisons in the network.
Assessment of inconsistency
If transitivity is met, direct and indirect evidence should 
yield consistent results. We will check carefully the net-
work for inconsistencies, because in a sample of medical 
network meta-analyses, about one-eighth of the networks 
were found to be inconsistent and leading to possible 
misinterpretation of results [48].
To evaluate consistency, local and global statisti-
cal methods will be used [49]. The design-by-treatment 
interaction test will examine the whole network [50], 
and the Separating Indirect from Direct Evidence (SIDE) 
approach will search for local inconsistencies [51]. Both 
will be fit using the netmeta package in R. In case of sig-
nificant inconsistency, we will investigate the possible 
sources of it (mistakes in data entry, clear differences in 
study characteristics), and if necessary, we will explore 
the inconsistency further by network meta-regression 
and subgroup analyses (see below).
Exploring heterogeneity and inconsistency
We expect the presence of some heterogeneity and 
inconsistency. We will explore the following potential 




3. Sex (percentage women).
4. Ethnicity.
5. Lifetime exposure to antipsychotics (if not available, 
duration of illness will be used as a proxy).
6. Antipsychotic dose.
7. Pharmaceutical sponsorship.
8. Time of recording the outcome since randomization.
Analyses to test the robustness of the results
We will perform the following sensitivity analyses on the 
primary outcome:
1. Exclusion of non-double-blind studies (open and sin-
gle-blind studies).
2. Analysis of only data of observed cases.
3. Exclusion of studies that did not use operationalized 
criteria to diagnose schizophrenia.
4. Exclusion of studies with an overall assessment of 
high risk of bias.
5.  Exclusion of studies in study participants with mini-
mal prior exposure to antipsychotics, in particular, 
trials in first-episode patients and most studies in 
children.
6. Exclusion of enriched design studies. In enriched 
design studies, trial participants are first stabilized on 
one compound and then randomized to either stay-
ing on the same compound or switching to another 
compound.
Publication bias
We will explore the association between study size and 
effect size with a comparison-adjusted funnel plot and 
with a contour enhanced funnel plot of all active drugs 
versus placebo (when at least 10 studies are available per 
outcome) [52]. Any asymmetry observed can be attrib-
uted to systematic differences between small and large 
studies, true heterogeneity or publication bias.
Statistical software
The analysis and presentation of results will be performed 
using self-programmed routines and the rjags, meta and 
netmeta package in R (details see above).
Assessment of the confidence in the evidence from NMA
We will evaluate the confidence in estimates of the pri-
mary outcome with the framework Confidence in 
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Network Meta-Analysis (CINeMA) [53, 54], imple-
mented in a web application [55].
Discussion
This network meta-analysis will examine the differences 
in metabolic side effects (comprising weight gain and dis-
turbances in lipid and glucose metabolisms) of antipsy-
chotic drugs during medium- to long-term treatment of 
individuals with schizophrenia.
We anticipate the following practical or operational 
issues involved in performing the review: First, we expect 
several hundreds of included studies for which data 
needs to be extracted in double. To handle this enor-
mous amount of information, we are planning to use a 
Microsoft Access database customized for this purpose 
allowing automatic comparison of data entries. Second, 
metabolic side effects will not have been systemati-
cally recorded in many, especially older, trials and may 
appear only in adverse event listings, which are typically 
reported incompletely in publications. Also in modern 
trials, reporting of metabolic parameters is not stand-
ardized and may be incomplete. Thus, we are planning 
to contact pharmaceutical companies and study authors 
to request for missing data. Third, a related and frequent 
problem is missing measures of variability of effect, i.e. 
standard deviations (SDs). In this case, we will calculate 
them from other reported statistical parameters as rec-
ommended by the Cochrane Handbook for Systematic 
Reviews of Interventions [42] or request missing SDs from 
the study authors. When no information can be obtained, 
we will derive SDs from those of the other studies using a 
validated imputation technique [56]. Fourth, several tri-
als will investigate different dose arms of the same drug. 
For the primary analysis, different doses (when within the 
recommended range [36]) will be pooled, but the effects 
of the dose will be explored in subgroup analysis.
Possible limitations at individual study and review lev-
els may arise from the following issues: The above-men-
tioned problem of missing data could potentially result in 
publication bias. We will assess this risk and include it in 
the CINeMA assessment. Another limitation at the study 
level is premature study discontinuations, which are fre-
quent in trials with participants with schizophrenia and 
which increase with longer study duration. Imputation 
methods used by the original authors aim to correct this 
issue but cannot fully overcome this problem. To investi-
gate whether premature study discontinuations substan-
tially impact the relative treatment effects (resulting in a 
limitation at the review level), we are planning a sensitiv-
ity analysis using completer data only. Moreover, we will 
extract premature discontinuations overall and for rea-
sons related to the outcomes and use this information to 
judge the risk of bias due to missing outcome data [24]; 
also, we will clearly state this issue in the limitation sec-
tion. Additionally, differences between comparisons in 
population characteristics (such as baseline weight, age, 
sex, ethnicity and previous exposure to antipsychotics), 
intervention characteristics (such as dose) and study 
characteristics (such as blinding, diagnostic criteria, risk 
of bias, enriched design, pharmaceutical sponsorship and 
trial duration) may modify treatment effects and can be a 
limitation at the review level. Therefore, we will include 
these characteristics in the transitivity assessment and 
explore their impact on the results in meta-regression 
and sensitivity analyses. Of note, the remaining differ-
ences that result in imprecise, heterogeneous and/or 
inconsistent treatment effects in the NMA will lead to 
lower confidence in the estimate in CINeMA.
If any protocol amendments, e.g. for additional analy-
ses to explore potential effect modifiers, will be needed, 
we will update the protocol record in PROSPERO and 
we will clearly state the changes to the protocol and their 
reasons in the resulting publication.
This network meta-analysis will summarize all avail-
able data from randomized controlled clinical trials to 
date and integrate direct evidence and indirect evidence. 
Thus, it can provide a comprehensive overview of the 
evidence with increased statistical power (by combining 
direct and indirect evidence) and with estimates available 
for comparisons of drugs that have not been compared in 
clinical trials so far (by using indirect evidence). It shall 
inform the choice of antipsychotic medication by indi-
viduals with schizophrenia and their physicians, thereby 
the side effect burden might be reduced and adherence to 
treatment increased which could improve the long-term 
outcome of this severe mental disorder.
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